NCT00248560 · OUTCOME

Survival

Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer · Source last updated 2019-03-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: months
Interval / dispersion: 95% Confidence Interval
Time frame: Every 8 weeks

What was measured

Overall Survival using the Kaplan-Meier method

Groups in this outcome

Gemcitabine, Docetaxel

Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Gemcitabine, Docetaxel	36

Reported measurements

Source class 1

Values in months · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Gemcitabine, Docetaxel	4.2	Not reported	2.4	7.0	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
2.4
upper Limit
7.0
value
4.2

denoms

counts
group Id
OG000
value
36
units
Participants

description

Overall Survival using the Kaplan-Meier method

dispersion Type

95% Confidence Interval

groups

description
Gemcitabine given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine.
id
OG000
title
Gemcitabine, Docetaxel

param Type

MEDIAN

reporting Status

POSTED

time Frame

Every 8 weeks

title

Survival

type

SECONDARY

unit Of Measure

months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice